Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/
Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/
Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.
Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/
Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/
Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/
Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.
Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258
Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/
Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/
Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/
Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/
Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/
Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/
Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/
Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/
Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/
Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/
Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/
Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/
Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/
Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/
Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/
Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.
#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
#12 Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: pubmed.ncbi.nlm.nih.gov/34807248/
A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/
Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34451967/
Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: pubmed.ncbi.nlm.nih.gov/33928459/
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: pubmed.ncbi.nlm.nih.gov/34510694/
Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: pubmed.ncbi.nlm.nih.gov/33774684/
Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34735411/
Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: pubmed.ncbi.nlm.nih.gov/34115709/.
COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: pubmed.ncbi.nlm.nih.gov/34257025/.
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: pubmed.ncbi.nlm.nih.gov/34836672/.
Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: pubmed.ncbi.nlm.nih.gov/34280870/
Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: pubmed.ncbi.nlm.nih.gov/34731748/
Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: pubmed.ncbi.nlm.nih.gov/34906409/
Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other...
#13 COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. www.ncbi.nlm.nih.gov/pubmed/34416319
Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. www.ncbi.nlm.nih.gov/pubmed/34092429
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. www.ncbi.nlm.nih.gov/pubmed/34025885
Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. www.ncbi.nlm.nih.gov/pubmed/34586408
Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. www.ncbi.nlm.nih.gov/pubmed/34756746
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. www.ncbi.nlm.nih.gov/pubmed/34432976
Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. www.ncbi.nlm.nih.gov/pubmed/34754400
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. www.ncbi.nlm.nih.gov/pubmed/34281357
Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. www.ncbi.nlm.nih.gov/pubmed/34835284
Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. www.ncbi.nlm.nih.gov/pubmed/34366403
Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. www.ncbi.nlm.nih.gov/pubmed/34564344
Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr...
#14 Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. www.ncbi.nlm.nih.gov/pubmed/34617315
Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695
Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382
Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459
Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657
Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012
Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. www.ncbi.nlm.nih.gov/pubmed/34547487
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. www.ncbi.nlm.nih.gov/pubmed/34339728
Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. www.ncbi.nlm.nih.gov/pubmed/34356586
Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. www.ncbi.nlm.nih.gov/pubmed/34219532
Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. www.ncbi.nlm.nih.gov/pubmed/34246585
Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. www.ncbi.nlm.nih.gov/pubmed/34492161
Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. www.ncbi.nlm.nih.gov/pubmed/34844930
Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. www.ncbi.nlm.nih.gov/pubmed/34487236
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. www.ncbi.nlm.nih.gov/pubmed/34551225
Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. www.ncbi.nlm.nih.gov/pubmed/34709227
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. www.ncbi.nlm.nih.gov/pubmed/34921468
Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. www.ncbi.nlm.nih.gov/pubmed/34824230
Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. www.ncbi.nlm.nih.gov/pubmed/34170372
Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. www.ncbi.nlm.nih.gov/pubmed/34849667
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. www.ncbi.nlm.nih.gov/pubmed/34646267
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. www.ncbi.nlm.nih.gov/pubmed/34127481
Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. www.ncbi.nlm.nih.gov/pubmed/34538306
Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. www.ncbi.nlm.nih.gov/pubmed/34237049
Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. www.ncbi.nlm.nih.gov/pubmed/33406694
Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. www.ncbi.nlm.nih.gov/pubmed/34660088
Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. www.ncbi.nlm.nih.gov/pubmed/34916217
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. www.ncbi.nlm.nih.gov/pubmed/34153517
Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. www.ncbi.nlm.nih.gov/pubmed/34668687
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis...
0k 16
Hemos deshabilitado la autenticación con Facebook. Si entras a Mediatize con una cuenta de Facebook, lee esto.
*
Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/
Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.
A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.
Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/
Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.
Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.
Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.
Relapse of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34591991/
Thrombosis in pre- and post-vaccination phase of COVID-19; pubmed.ncbi.nlm.nih.gov/34650382/
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: pubmed.ncbi.nlm.nih.gov/34786893/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34790811/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: pubmed.ncbi.nlm.nih.gov/34629931/
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/
Autoimmune roots of thrombotic events after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34508917/.
New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca
Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: pubmed.ncbi.nlm.nih.gov/34796065/.
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): pubmed.ncbi.nlm.nih.gov/34595867/
A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): pubmed.ncbi.nlm.nih.gov/34820240/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: pubmed.ncbi.nlm.nih.gov/33851389/
Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: pubmed.ncbi.nlm.nih.gov/33980419/
Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34264151/
Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: pubmed.ncbi.nlm.nih.gov/34734086/
Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: pubmed.ncbi.nlm.nih.gov/34755555/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34264514/.
Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34840204/
Neurological side effects of SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34750810/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: pubmed.ncbi.nlm.nih.gov/34571653/.
Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: pubmed.ncbi.nlm.nih.gov/34835275/.
Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: pubmed.ncbi.nlm.nih.gov/34659839/.
Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34668274/.
Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34549821/
Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): pubmed.ncbi.nlm.nih.gov/34528522/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/.
Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Myocarditis Following mRNA COVID-19 Vaccine: journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: pubmed.ncbi.nlm.nih.gov/34614328/.
Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/
Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: pubmed.ncbi.nlm.nih.gov/34246586/
Hypersensitivity Myocarditis and...
*
Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7.
Acute myocardial infarction and myocarditis after COVID-19 vaccination: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
Myocarditis after Covid-19 vaccination in a large healthcare organization: www.nejm.org/doi/10.1056/NEJMoa2110737
Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052
Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=
STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. pubmed.ncbi.nlm.nih.gov/34756746/
Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
Myocarditis after COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34546329/.
Patients with acute myocarditis after COVID-19 mRNA vaccination:. jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
Myocarditis after COVID-19 vaccination: a case series: www.sciencedirect.com/science/article/pii/S0264410X21011725?via=ihub.
Myocarditis associated with COVID-19 vaccination in adolescents: publications.aap.org/pediatrics/article/148/5/e2021053427/181357
Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. pubmed.ncbi.nlm.nih.gov/34704459/
Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230.
Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
Myocarditis after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S2352906721001603
Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.
Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administ.
Myocarditis associated with COVID-19 mRNA vaccination: pubs.rsna.org/doi/10.1148/radiol.2021211430
Acute myocarditis after COVID-19 vaccination: a case report: www.sciencedirect.com/science/article/pii/S0248866321007098
Acute myopericarditis after COVID-19 vaccination in adolescents:. pubmed.ncbi.nlm.nih.gov/34589238/.
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: academic.oup.com/jpids/article/10/10/962/6329543.
Acute myocarditis associated with anti-COVID-19 vaccination: ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. pubmed.ncbi.nlm.nih.gov/34428917/.
Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. pubmed.ncbi.nlm.nih.gov/34088762/.
Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6.
COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: www.mdpi.com/2036-7503/13/3/61.
Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34402228/
Myocarditis temporally associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34133885/
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/
Acute myocarditis associated with COVID-19 vaccination: report of a case: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: pubmed.ncbi.nlm.nih.gov/34840235/.
Myocarditis in the setting of a recent COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34712497/.
Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/
Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.
Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34615534/
Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34352418/
Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/
Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: haematologica.org/article/view/haematol.2021.279075
COVID-19 vaccine-induced thrombosis: pubmed.ncbi.nlm.nih.gov/34802488/.
Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.
Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34863404/.
Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: www.sciencedirect.com/science/article/pii/S235255682100093X
Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34876440/
Deep venous thrombosis more than two weeks after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33928773/
Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/
Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34587242/
Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/
Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/
Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.
Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258
Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: pubmed.ncbi.nlm.nih.gov/34579636/
Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/
Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/
Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): pubmed.ncbi.nlm.nih.gov/33624509/.
Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/
Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/
Myocarditis associated with COVID-19 vaccination in three adolescent boys: pubmed.ncbi.nlm.nih.gov/34851078/.
Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/
Perimyocarditis...
*
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: pubmed.ncbi.nlm.nih.gov/34849657/.
Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/
Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: pubmed.ncbi.nlm.nih.gov/34605853/
Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/
Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34744118/
Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: pubmed.ncbi.nlm.nih.gov/34334935/.
Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/
Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/
Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: pubmed.ncbi.nlm.nih.gov/34185045/
Myocarditis after BNT162b2 vaccination in a healthy male: pubmed.ncbi.nlm.nih.gov/34229940/
Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/
Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34308326/.
Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/
Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/
Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/
Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/
Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/
Acute myocarditis in a young adult two days after vaccination with Pfizer: pubmed.ncbi.nlm.nih.gov/34709227/
Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/
Acute myocarditis after 2019 coronavirus disease vaccination: pubmed.ncbi.nlm.nih.gov/34734821/
A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: pubmed.ncbi.nlm.nih.gov/34246585/
Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34228985/
Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34852213/
Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: pubmed.ncbi.nlm.nih.gov/34866122/
Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: pubmed.ncbi.nlm.nih.gov/34601566/
Myocarditis following COVID-19 vaccination: MRI study: pubmed.ncbi.nlm.nih.gov/34739045/.
Acute myocarditis after COVID-19 vaccination: case report: docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: pubmed.ncbi.nlm.nih.gov/34374740/
Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: pubmed.ncbi.nlm.nih.gov/34865500/
Myocarditis following vaccination with Covid-19 in a large healthcare organization: pubmed.ncbi.nlm.nih.gov/34614329/
AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: pubmed.ncbi.nlm.nih.gov/34560365/
COVID-19, Guillain-Barré and vaccineA dangerous mix: pubmed.ncbi.nlm.nih.gov/34108736/.
Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.
Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: link.springer.com/article/10.1007/s10072-021-05523-5.
COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: onlinelibrary.wiley.com/doi/10.1002/ana.26258.
Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: jamanetwork.com/journals/jama/fullarticle/2785009
A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34567447/
Guillain-Barré syndrome associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34648420/.
Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2783708
Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34114256/.
Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34767184/.
Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: pubmed.ncbi.nlm.nih.gov/34644738/.
Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: pubmed.ncbi.nlm.nih.gov/34649856/
A rare case of Guillain-Barré syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34671572/
Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33758714/
COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: pubmed.ncbi.nlm.nih.gov/34484780/
Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; pubmed.ncbi.nlm.nih.gov/34779385/.
Miller Fisher syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34817727/.
Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: pubmed.ncbi.nlm.nih.gov/34789193/.
Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261746/
Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: pubmed.ncbi.nlm.nih.gov/34217513/.
*
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.
A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.
Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.
Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.
Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/
Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34697502/
Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: pubmed.ncbi.nlm.nih.gov/33858693/
Acute transverse myelitis following inactivated COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34370410/
Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34579245/.
A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: pubmed.ncbi.nlm.nih.gov/34182207/
Post COVID-19 transverse myelitis; a case report with review of the literature: pubmed.ncbi.nlm.nih.gov/34457267/.
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Acute pericarditis and cardiac tamponade after vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34749492/
Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34849667/
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34319393/
Acute myopericarditis after COVID-19 vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34589238/
Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34149145/
Case report: symptomatic pericarditis post COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34693198/.
An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: pubmed.ncbi.nlm.nih.gov/34797392/
Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): pubmed.ncbi.nlm.nih.gov/34862234/
Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: pubmed.ncbi.nlm.nih.gov/34396358/.
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34591186/
Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34352309/
Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: pubmed.ncbi.nlm.nih.gov/34804803/.
Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: pubmed.ncbi.nlm.nih.gov/34077572/
Retinal hemorrhage after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34884407/.
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34783899/
Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34549178/.
Brain death in a vaccinated patient with COVID-19 infection: pubmed.ncbi.nlm.nih.gov/34656887/
Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34236717/.
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33932458/
Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: pubmed.ncbi.nlm.nih.gov/34092400/742.
Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34754937/
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34846583/
COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: pubmed.ncbi.nlm.nih.gov/33851711/
Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: pubmed.ncbi.nlm.nih.gov/34675550/.
Anaphylaxis after Modern COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34734159/.
Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34698847/
Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: pubmed.ncbi.nlm.nih.gov/34020815/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
Acute myocardial infarction and myocarditis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34586408/
Takotsubo syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34539938/.
Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: pubmed.ncbi.nlm.nih.gov/34731486/.
Premature myocardial infarction or side effect of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33824804/
Myocardial infarction, stroke, and pulmonary embolism...
*
Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34148772/
Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: pubmed.ncbi.nlm.nih.gov/34702550/
Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty
Deaths associated with recently launched SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34425384/
A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/
COVID-19 vaccine-induced urticarial vasculitis: pubmed.ncbi.nlm.nih.gov/34369046/.
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34280507/.
New-onset leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34241833/
Cutaneous small vessel vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34529877/.
Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928638/
Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34836739/
Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; pubmed.ncbi.nlm.nih.gov/34495381/.
Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34327795
Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34660867/.
Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/
Reactivation of IgA vasculitis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34848431/
Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34310759/.
Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: pubmed.ncbi.nlm.nih.gov/34720009/
A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34518812/
Cutaneous vasculitis following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34611627/.
Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: pubmed.ncbi.nlm.nih.gov/34705320/.
IgA vasculitis following COVID-19 vaccination in an adult: pubmed.ncbi.nlm.nih.gov/34779011/
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34451967/
Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: pubmed.ncbi.nlm.nih.gov/33928459/
Reactivation of IgA vasculitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34250509/
Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34292611/.
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: pubmed.ncbi.nlm.nih.gov/34530771/.
Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: pubmed.ncbi.nlm.nih.gov/34245294/.
Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34599716/.
Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: pubmed.ncbi.nlm.nih.gov/34115904/.
Henoch-Schönlein purpura occurring after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34247902/.
Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: pubmed.ncbi.nlm.nih.gov/34696186/.
Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34237323/.
Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34851795/.
A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34849386/
Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34310763/
Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34251683/.
Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: pubmed.ncbi.nlm.nih.gov/34557622/.
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: pubmed.ncbi.nlm.nih.gov/34510694/
Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: pubmed.ncbi.nlm.nih.gov/34713472/803
Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34819272/
Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34337124/
Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: pubmed.ncbi.nlm.nih.gov/34535924/
Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: www.frontiersin.org/articles/10.3389/fmed.2021.798095/
COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: pubmed.ncbi.nlm.nih.gov/33591026/
Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: pubmed.ncbi.nlm.nih.gov/33625300/
Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: pubmed.ncbi.nlm.nih.gov/33774684/
Lymphadenopathy after COVID-19 vaccination: review of imaging findings: pubmed.ncbi.nlm.nih.gov/33985872/
Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34735411/
Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: pubmed.ncbi.nlm.nih.gov/34115709/.
COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: pubmed.ncbi.nlm.nih.gov/34257025/.
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: pubmed.ncbi.nlm.nih.gov/34836672/.
Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: pubmed.ncbi.nlm.nih.gov/34280870/
COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: pubmed.ncbi.nlm.nih.gov/34432391/
Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: pubmed.ncbi.nlm.nih.gov/34731748/
Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: pubmed.ncbi.nlm.nih.gov/34906409/
Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/
A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other...
*
Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.
Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/
Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.
New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.
Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/
ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/
Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.
Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/
COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.
Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.
Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/
A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.
Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/
Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.
New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.
Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/
ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/
Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.
Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/
COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.
Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.
Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. www.ncbi.nlm.nih.gov/pubmed/34416319
Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. www.ncbi.nlm.nih.gov/pubmed/34092429
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. www.ncbi.nlm.nih.gov/pubmed/34025885
Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. www.ncbi.nlm.nih.gov/pubmed/34586408
Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. www.ncbi.nlm.nih.gov/pubmed/34756746
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. www.ncbi.nlm.nih.gov/pubmed/34432976
Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. www.ncbi.nlm.nih.gov/pubmed/34754400
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. www.ncbi.nlm.nih.gov/pubmed/34281357
Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. www.ncbi.nlm.nih.gov/pubmed/34835284
Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. www.ncbi.nlm.nih.gov/pubmed/34366403
Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. www.ncbi.nlm.nih.gov/pubmed/34564344
Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr...
*
Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695
Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382
Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459
Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657
Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012
Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. www.ncbi.nlm.nih.gov/pubmed/34547487
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. www.ncbi.nlm.nih.gov/pubmed/34339728
Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. www.ncbi.nlm.nih.gov/pubmed/34356586
Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. www.ncbi.nlm.nih.gov/pubmed/34219532
Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. www.ncbi.nlm.nih.gov/pubmed/34246585
Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. www.ncbi.nlm.nih.gov/pubmed/34492161
Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. www.ncbi.nlm.nih.gov/pubmed/34844930
Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. www.ncbi.nlm.nih.gov/pubmed/34487236
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. www.ncbi.nlm.nih.gov/pubmed/34551225
Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. www.ncbi.nlm.nih.gov/pubmed/34709227
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. www.ncbi.nlm.nih.gov/pubmed/34921468
Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. www.ncbi.nlm.nih.gov/pubmed/34824230
Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. www.ncbi.nlm.nih.gov/pubmed/34170372
Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. www.ncbi.nlm.nih.gov/pubmed/34849667
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. www.ncbi.nlm.nih.gov/pubmed/34646267
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. www.ncbi.nlm.nih.gov/pubmed/34127481
Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. www.ncbi.nlm.nih.gov/pubmed/34538306
Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. www.ncbi.nlm.nih.gov/pubmed/34237049
Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. www.ncbi.nlm.nih.gov/pubmed/33406694
Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. www.ncbi.nlm.nih.gov/pubmed/34660088
Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. www.ncbi.nlm.nih.gov/pubmed/34916217
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. www.ncbi.nlm.nih.gov/pubmed/34153517
Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. www.ncbi.nlm.nih.gov/pubmed/34668687
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis...